PubMed=233137; DOI=10.1038/282615a0
Aden D.P., Fogel A., Plotkin S.A., Damjanov I., Knowles B.B.
Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line.
Nature 282:615-616(1979)
PubMed=6248960; DOI=10.1126/science.6248960
Knowles B.B., Howe C.C., Aden D.P.
Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen.
Science 209:497-499(1980)
Patent=US4393133
Knowles B.B., Aden D.P.
Human hepatoma derived cell line, process for preparation thereof, and uses therefor.
Patent number US4393133, 12-Jul-1983
PubMed=2439335; DOI=10.1111/j.1432-1033.1987.tb11497.x
Vincent C., Marceau M., Blangarin P., Bouic P., Madjar J.J., Revillard J.-P.
Purification of alpha 1-microglobulin produced by human hepatoma cell lines. Biochemical characterization and comparison with alpha 1-microglobulin synthesized by human hepatocytes.
Eur. J. Biochem. 165:699-704(1987)
PubMed=8384076; DOI=10.1016/0165-4608(93)90227-D
Chen H.-L., Chiu T.-S., Chen P.-J., Chen D.-S.
Cytogenetic studies on human liver cancer cell lines.
Cancer Genet. Cytogenet. 65:161-166(1993)
PubMed=8389256; DOI=10.1093/carcin/14.5.987
Hsu I.C., Tokiwa T., Bennett W., Metcalf R.A., Welsh J.A., Sun T., Harris C.C.
p53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines.
Carcinogenesis 14:987-992(1993)
PubMed=8050184; DOI=10.1111/j.1365-2249.1994.tb06089.x
Wadee A.A., Paterson A., Coplan K.A., Reddy S.G.
HLA expression in hepatocellular carcinoma cell lines.
Clin. Exp. Immunol. 97:328-333(1994)
PubMed=8835345; DOI=10.1002/(SICI)1096-9071(199602)48:2
Tsuboi S., Nagamori S., Miyazaki M., Mihara K., Fukaya K., Teruya K., Kosaka T., Tsuji T., Namba M.
Persistence of hepatitis C virus RNA in established human hepatocellular carcinoma cell lines.
J. Med. Virol. 48:133-140(1996)
DOI=10.11418/jtca1981.16.3_173
Mihara K., Miyazaki M., Fushimi K., Tsuji T., Inoue Y., Fukaya K.-I., Ohashi R., Namba M.
The p53 gene status and other cellular characteristics of human cell lines maintained in our laboratory.
Tissue Cult. Res. Commun. 16:173-178(1997)
PubMed=9178645; DOI=10.1006/cimm.1997.1108
Nakao M., Sata M., Saitsu H., Yutani S., Kawamoto M., Kojiro M., Itoh K.
CD4+ hepatic cancer-specific cytotoxic T lymphocytes in patients with hepatocellular carcinoma.
Cell. Immunol. 177:176-181(1997)
PubMed=9359923; DOI=10.18926/AMO/30789
Mihara K., Miyazaki M., Kondo T., Fushimi K., Tsuji T., Inoue Y., Fukaya K.-I., Ishioka C., Namba M.
Yeast functional assay of the p53 gene status in human cell lines maintained in our laboratory.
Acta Med. Okayama 51:261-265(1997)
PubMed=11050057; DOI=10.1053/jhep.2000.19349
Wong N., Lai P., Pang E., Leung T.W.-T., Lau J.W.-L., Johnson P.J.
A comprehensive karyotypic study on human hepatocellular carcinoma by spectral karyotyping.
Hepatology 32:1060-1068(2000)
PubMed=12029633; DOI=10.1053/jhep.2002.33683
Yasui K., Arii S., Zhao C., Imoto I., Ueda M., Nagai H., Emi M., Inazawa J.
TFDP1, CUL4A, and CDC16 identified as targets for amplification at 13q34 in hepatocellular carcinomas.
Hepatology 35:1476-1484(2002)
PubMed=12068308; DOI=10.1038/nature00766
Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C., Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.
Mutations of the BRAF gene in human cancer.
Nature 417:949-954(2002)
DOI=10.1385/CP:1:3-4:313
Pang R.T.K., Poon T.C.W., Wong N., Lai P.B.-S., Wong N.L.Y., Chan C.M.L., Yu J.W.S., Chan A.T.C., Sung J.J.Y.
Comparison of protein expression patterns between hepatocellular carcinoma cell lines and a hepatoblastoma cell line.
Clin. Proteomics 1:313-331(2004)
PubMed=14980111
Zhai B.-J., Wu F., Shao Z.-Y., Hu K., Zhao C.L., Wang Z.-B.
Establishment of human hepatocellular carcinoma multidrug-resistance cell line (HepG2/Adm) and study apoptosis induced by low-frequency pulse ultrasound exposure.
Zhonghua Gan Zang Bing Za Zhi 12:95-98(2004)
PubMed=15767549; DOI=10.1158/1535-7163.MCT-04-0234
Nakatsu N., Yoshida Y., Yamazaki K., Nakamura T., Dan S., Fukui Y., Yamori T.
Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays.
Mol. Cancer Ther. 4:399-412(2005)
PubMed=17254797; DOI=10.1016/j.biologicals.2006.10.001
Azari S., Ahmadi N., Tehrani M.J., Shokri F.
Profiling and authentication of human cell lines using short tandem repeat (STR) loci: report from the National Cell Bank of Iran.
Biologicals 35:195-202(2007)
PubMed=19751877; DOI=10.1016/j.humpath.2009.07.003
Lopez-Terrada D.H., Cheung S.W., Finegold M.J., Knowles B.B.
Hep G2 is a hepatoblastoma-derived cell line.
Hum. Pathol. 40:1512-1515(2009)
PubMed=20069059; DOI=10.1155/2010/437143
Srisomsap C., Sawangareetrakul P., Subhasitanont P., Chokchaichamnankit D., Chiablaem K., Bhudhisawasdi V., Wongkham S., Svasti J.
Proteomic studies of cholangiocarcinoma and hepatocellular carcinoma cell secretomes.
J. Biomed. Biotechnol. 2010:437143-437143(2010)
PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)
PubMed=20228232; DOI=10.1124/dmd.109.031831
Hart S.N., Li Y., Nakamoto K., Subileau E.-A., Steen D., Zhong X.-B.
A comparison of whole genome gene expression profiles of HepaRG cells and HepG2 cells to primary human hepatocytes and human liver tissues.
Drug Metab. Dispos. 38:988-994(2010)
PubMed=20937217; DOI=10.1170/149
Di Masi A., Viganotti M., Antoccia A., Magrelli A., Salvatore M., Azzalin G., Tosto F., Lorenzetti S., Maranghi F., Mantovani A., Macino G., Tanzarella C., Taruscio D.
Characterization of HuH6, Hep3B, HepG2 and HLE liver cancer cell lines by WNT/beta - catenin pathway, microRNA expression and protein expression profile.
Cell. Mol. Biol. 56:OL1299-OL1317(2010)
PubMed=21269460; DOI=10.1186/1752-0509-5-17
Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Burckstummer T., Bennett K.L., Superti-Furga G., Colinge J.
Initial characterization of the human central proteome.
BMC Syst. Biol. 5:17-17(2011)
PubMed=22278370; DOI=10.1074/mcp.M111.014050
Geiger T., Wehner A., Schaab C., Cox J., Mann M.
Comparative proteomic analysis of eleven common cell lines reveals ubiquitous but varying expression of most proteins.
Mol. Cell. Proteomics 11:M111.014050-M111.014050(2012)
PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)
PubMed=23325432; DOI=10.1101/gr.147942.112
Varley K.E., Gertz J., Bowling K.M., Parker S.L., Reddy T.E., Pauli-Behn F., Cross M.K., Williams B.A., Stamatoyannopoulos J.A., Crawford G.E., Absher D.M., Wold B.J., Myers R.M.
Dynamic DNA methylation across diverse human cell lines and tissues.
Genome Res. 23:555-567(2013)
PubMed=23505090; DOI=10.1002/hep.26402
Wang K., Lim H.Y., Shi S., Lee J., Deng S., Xie T., Zhu Z., Wang Y., Pocalyko D., Yang W.J., Rejto P.A., Mao M., Park C.-K., Xu J.
Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma.
Hepatology 58:706-717(2013)
PubMed=23887712; DOI=10.1038/ncomms3218
Nault J.-C., Mallet M., Pilati C., Calderaro J., Bioulac-Sage P., Laurent C., Laurent A., Cherqui D., Balabaud C., Zucman-Rossi J.
High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions.
Nat. Commun. 4:2218-2218(2013)
PubMed=24116068; DOI=10.1371/journal.pone.0075692
Weiskirchen R., Weimer J., Meurer S.K., Kron A., Seipel B., Vater I., Arnold N., Siebert R., Xu L.-M., Friedman S.L., Bergmann C.
Genetic characteristics of the human hepatic stellate cell line LX-2.
PLoS ONE 8:E75692-E75692(2013)
PubMed=24618588; DOI=10.1371/journal.pone.0091433
Chernobrovkin A.L., Zubarev R.A.
Detection of viral proteins in human cells lines by xeno-proteomics: elimination of the last valid excuse for not testing every cellular proteome dataset for viral proteins.
PLoS ONE 9:E91433-E91433(2014)
PubMed=25960936; DOI=10.4161/21624011.2014.954893
Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.
A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.
OncoImmunology 3:E954893-E954893(2014)
PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H., Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)
PubMed=25574106; DOI=10.3748/wjg.v21.i1.311
Cevik D., Yildiz G., Ozturk M.
Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations.
World J. Gastroenterol. 21:311-317(2015)
PubMed=26160117; DOI=10.1093/toxsci/kfv136
Sison-Young R.L.C., Mitsa D., Jenkins R.E., Mottram D., Alexandre E., Richert L., Aerts H., Weaver R.J., Jones R.P., Johann E., Hewitt P.G., Ingelman-Sundberg M., Goldring C.E.P., Kitteringham N.R., Park B.K.
Comparative proteomic characterization of 4 human liver-derived single cell culture models reveals significant variation in the capacity for drug disposition, bioactivation, and detoxication.
Toxicol. Sci. 147:412-424(2015)
PubMed=26825538; DOI=10.1016/j.jprot.2016.01.016
Wisniewski J.R., Vildhede A., Noren A., Artursson P.
In-depth quantitative analysis and comparison of the human hepatocyte and hepatoma cell line HepG2 proteomes.
J. Proteomics 136:234-247(2016)
PubMed=27329724; DOI=10.18632/oncotarget.10161
Watari K., Nishitani A., Shibata T., Noda M., Kawahara A., Akiba J., Murakami Y., Yano H., Kuwano M., Ono M.
Phosphorylation of mTOR Ser2481 is a key target limiting the efficacy of rapalogs for treating hepatocellular carcinoma.
Oncotarget 7:47403-47417(2016)
PubMed=27470094; DOI=10.1016/j.chroma.2016.07.042
Liu Z.-Y., Wang F.-J., Chen J., Zhou Y., Zou H.-F.
Modulating the selectivity of affinity absorbents to multi-phosphopeptides by a competitive substitution strategy.
J. Chromatogr. A 1461:35-41(2016)
PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)
PubMed=29610054; DOI=10.1016/j.dmpk.2018.03.003
Shi J., Wang X., Lyu L., Jiang H., Zhu H.-J.
Comparison of protein expression between human livers and the hepatic cell lines HepG2, Hep3B, and Huh7 using SWATH and MRM-HR proteomics: Focusing on drug-metabolizing enzymes.
Drug Metab. Pharmacokinet. 33:133-140(2018)
PubMed=29660373; DOI=10.1016/j.bbagen.2018.04.012
Touat-Hamici Z., Bulteau A.-L., Bianga J., Jean-Jacques H., Szpunar J., Lobinski R., Chavatte L.
Selenium-regulated hierarchy of human selenoproteome in cancerous and immortalized cells lines.
Biochim. Biophys. Acta 1862:2493-2505(2018)
PubMed=30864654; DOI=10.1093/nar/gkz169
Zhou B., Ho S.S., Greer S.U., Spies N., Bell J.M., Zhang X., Zhu X., Arthur J.G., Byeon S., Pattni R., Saha I., Huang Y., Song G., Perrin D., Wong W.H., Ji H.P., Abyzov A., Urban A.E.
Haplotype-resolved and integrated genome analysis of the cancer cell line HepG2.
Nucleic Acids Res. 47:3846-3861(2019)
PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)
PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)
PubMed=31378681; DOI=10.1016/j.ccell.2019.07.001
Qiu Z.-X., Li H., Zhang Z.-T., Zhu Z.-F., He S., Wang X.-J., Wang P.-C., Qin J.-J., Zhuang L.-P., Wang W., Xie F.-B., Gu Y., Zou K.-K., Li C., Li C., Wang C.-H., Cen J., Chen X.-T., Shu Y.-J., Zhang Z., Sun L.-L., Min L.-H., Fu Y., Huang X.-W., Lv H., Zhou H., Ji Y., Zhang Z.-G., Meng Z.-Q., Shi X.-L., Zhang H.-B., Li Y.-X., Hui L.-J.
A pharmacogenomic landscape in human liver cancers.
Cancer Cell 36:179-193.e11(2019)
PubMed=31395879; DOI=10.1038/s41467-019-11415-2
Yu K., Chen B., Aran D., Charalel J., Yau C., Wolf D.M., van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.
Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types.
Nat. Commun. 10:3574-3574(2019)
PubMed=31561354; DOI=10.3233/CH-199226
Schulz C., Kammerer S., Kupper J.-H.
NADPH-cytochrome P450 reductase expression and enzymatic activity in primary-like human hepatocytes and HepG2 cells for in vitro biotransformation studies.
Clin. Hemorheol. Microcirc. 73:249-260(2019)
PubMed=31978347; DOI=10.1016/j.cell.2019.12.023
Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III, Kalocsay M., Jane-Valbuena J., Gelfand E., Schweppe D.K., Jedrychowski M., Golji J., Porter D.A., Rejtar T., Wang Y.K., Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A., Sellers W.R., Gygi S.P.
Quantitative proteomics of the Cancer Cell Line Encyclopedia.
Cell 180:387-402.e16(2020)
PubMed=32471280; DOI=10.3390/ijms21113813
Kiseleva O., Ponomarenko E., Poverennaya E.
Empowering shotgun mass spectrometry with 2DE: a HepG2 study.
Int. J. Mol. Sci. 21:3813.1-3813.16(2020)
400 179 0116
![Hep G2 [HEPG2]人肝癌細(xì)胞](/uploads/20240625/6bed061ac722d32c5f2673df6e88c083.png)
